RAW細(xì)胞 
	
		生長狀態(tài):	貼壁生長
	
	
		運(yùn)輸方式:	凍存運(yùn)輸
	
	
		細(xì)胞形態(tài):	上皮樣
	
	
		年限:	grade IV
	
	
		組織來源:	cerebrum; right temporal lobe
	
	
		ATCC Number:	CRL-2610?
	
	
		相關(guān)**:	其他**
	
	
		是否是腫瘤細(xì)胞:	0
	
	
		物種來源:	人
	
	
		器官來源:	大腦
	
	
		數(shù)量:	大量
	
	
		RAW細(xì)胞Designations:	LN-18
	
	
		Depositors:	 N de Tribolet
	
	
		Biosafety Level:	1
	
	
		Shipped:	frozen
	
	
		Medium & Serum:	See Propagation
	
	
		Growth Properties:	adherent
	
	
		Organism:	Homo sapiens
	
	
		Morphology:	epithelial
	
	
		
	
	
		Source:	Organ: brain
	
	
		Tissue: cerebrum; right temporal lobe
	
	
		Tumor Stage: grade IV
	
	
		Disease: glioblastoma; glioma
	
	
		Cellular Products:	fibronectin [51571]
	
	
		Permits/Forms: RAW細(xì)胞In addition to the MTA mentioned above, other ATCC and/or regulatory permits may be required for the transfer of this ATCC material. Anyone purchasing ATCC material is ultimately responsible for obtaining the permits. Please click here for information regarding the specific requirements for shipment to your location.
	
	
		Isolation:	Isolation date: 1976
	
	
		Tumorigenic:	Yes
	
	
		Oncogene:	p53 + (mutated, TGT (Cys) --> TCT (Ser) mutation at codon 238), PTEN + (wild type), p16 - (deleted), p14ARF - (deleted)
	
	
		Antigen Expression:	HLA A2, A9, B5, BW35, DRW3 [51571]
	
	
		DNA Profile (STR):	Amelogenin: X,Y
	
	
		CSF1PO: 12
	
	
		D13S317: 12,13
	
	
		D16S539: 11,13
	
	
		D5S818: 11,13
	
	
		D7S820: 8,10
	
	
		THO1: 9
	
	
		TPOX: 8
	
	
		vWA: 17,18
	
	
		Age:	65 years
	
	
		Gender:	male
	
	
		RAW細(xì)胞Ethnicity:	White
	
	
		Comments:	The LN-18 cell line was established in 1976 from cells taken from a patient with a right temporal lobe glioma. The cells are poorly differentiated. [51571] [51573] [55488]
	
	
		The cells are negative for glial fibrillary acidic proteins and S100 (S-100) protein. [51571]
	
	
		The cells exhibit mutated p53 (TP53) and possible homozygous deletions in the p16 and p14ARF tumor suppressor genes. They have a wild-type PTEN gene. [51573]
	
	
		Stimulation of the cells with Fas ligand lead to apoptotic cell death within 16 hours. The cells were also killed by puromycin in a dose dependent manner. [53380]
	
	
		Bcl-2 protects these cells from Fas ligand-induced cell death but was shown to have only a small protective effect on puromycin-induced apoptosis. [53380]
	
	
		This cell line is used in studies on apoptosis.
	
	
		Propagation:	ATCC complete growth medium: The base medium for this cell line is ATCC-formulated Dulbecco's Modified Eagle's Medium, Catalog No. 30-2002. To make the complete growth medium, add the following components to the base medium: fetal bovine serum to a final concentration of 5%.
	
	
		Atmosphere: air, 95%; carbon dioxide (CO2), 5%
	
	
		Temperature: 37.0°C
	
	
		Subculturing:	Protocol:
	
	
		Remove and discard culture medium.
	
	
		Briefly rinse the cell layer with 0.25% (w/v) Trypsin - 0.53 mM EDTA solution to remove all traces of serum that contains trypsin inhibitor.
	
	
		Add 2.0 to 3.0 ml of Trypsin-EDTA solution to flask and observe cells under an inverted microscope until cell layer is dispersed (usually within 5 to 15 minutes).
	
	
		Note: RAW細(xì)胞To avoid clumping do not agitate the cells by hitting or shaking the flask while waiting for the cells to detach. Cells that are difficult to detach may be placed at 37C to facilitate dispersal.
	
	
		Add 6.0 to 8.0 ml of complete growth medium and aspirate cells by gently pipetting.
	
	
		Add appropriate aliquots of the cell suspension to new culture vessels.
	
	
		Incubate cultures at 37C.
	
	
		
	
	
		Subcultivation Ratio: A subcultivation ratio of 1:4 to 1:6 is recommended
	
	
		Medium Renewal: Every 2 to 3 days
	
	
		Preservation:	Freeze medium: Complete growth medium, 90%; additional fetal bovine serum, 5%; DMSO, 5%
	
	
		Storage temperature: liquid nitrogen vapor phase
	
	
		Related Products:	Recommended medium (without the additional supplements or serum described under ATCC Medium):ATCC 30-2002
	
	
		recommended serum:ATCC 30-2020
	
	
		0.25% (w/v) Trypsin - 0.53 mM EDTA in Hank' BSS (w/o Ca++, Mg++):ATCC 30-2101
	
	
		Cell culture tested DMSO:ATCC 4-X
	
	
		References:	51571: Diserens AC, et al. Characterization of an established human malignant glioma cell line: LN-18. Acta Neuropathol. 53: 21-28, 1981. PubMed: 7211194
	
	
		51573: Ishii N, et al. Frequent co-alterations of TP53, p16/CDKN2A, p14ARF, PTEN tumor suppressor genes in human glioma cell lines. Brain Pathol. 9: 469-479, 1999. PubMed: 10416987
	
	
		53380: Schlapbach R, Fontana A. RAW細(xì)胞Differential activity of bcl-2 and ICE enzyme family protease inhibitors on Fas and puromycin-induced apoptosis of glioma cells.. Biochim. Biophys. Acta 1359: 174-180, 1997. PubMed: 9409814
	
	
		55488: Flaman JM, et al. A simple p53 functional assay for screening cell lines, blood, and tumors. Proc. Natl. Acad. Sci. USA 92: 3963-3967, 1995. PubMed: 7732013